Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).
James R. Berenson
Consultant or Advisory Role - Onyx
Honoraria - Onyx
Research Funding - Onyx
James D. Hilger
No relevant relationships to disclose
Robert Dichmann
No relevant relationships to disclose
Dipti Patel-Donnelly
No relevant relationships to disclose
Ralph V. Boccia
Consultant or Advisory Role - Onyx
Honoraria - Onyx
Alberto Bessudo
No relevant relationships to disclose
Laura Stampleman
No relevant relationships to disclose
Donald Gravenor
No relevant relationships to disclose
Shahrooz Eshaghian
No relevant relationships to disclose
Hilda Chamras
No relevant relationships to disclose
Youram Nassir
No relevant relationships to disclose
Regina A. Swift
Consultant or Advisory Role - Onyx
Honoraria - Onyx
Robert A. Vescio
No relevant relationships to disclose